Doxycycline Plus Streptomycin Versus Ciprofloxacin Plus Rifampicin in Spinal Brucellosis

Submission date Recruitment status Prospectively registered 22/03/2006 No longer recruiting [] Protocol Statistical analysis plan Registration date Overall study status 29/03/2006 Completed [X] Results [] Individual participant data Last Edited Condition category Infections and Infestations 13/10/2009

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Emine Alp

Contact details

Department of Infectious Disease Erciyes University Medical School Kayseri Türkiye 38039 ealp@erciyes.edu.tr

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers 04/131

Study information

Scientific Title

Study objectives

Ciprofloxacin plus rifampicin may be an alternative treatment regimen to doxycycline plus streptomycin in the treatment of spinal brucellosis

Ethics approval required

Old ethics approval format

Ethics approval(s)

Yes, Approved by the Ethical Committee of Erciyes University, approval date: 4/05/2001, reference number: 04/131

Study design

An open, controlled and non-randomized trial

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Brucellosis is an infectious disease affecting multiple systems including vertebrae

Interventions

To compare the efficacy, adverse drug reactions, complications and cost of ciprofloxacin plus rifampicin versus doxycycline plus streptomycin in the treatment of spinal brucellosis

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Doxycycline, streptomycin, ciprofloxacin, rifampicin

Primary outcome measure

- 1. Clinical efficacy of ciprofloxacin plus rifampicin in spinal brucellosis
- 2. The prevalence of relapses

Secondary outcome measures

The cost of the two regimens

Overall study start date

01/01/2002

Completion date

31/12/2004

Eligibility

Key inclusion criteria

The patients diagnosed with spinal brucellosis between January 2002 to December 2004 were enrolled into two study groups consecutively

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

31 patients

Key exclusion criteria

- 1. Age less than 16 years
- 2. Pregnancy
- 3. Neurobrucellosis
- 4. Previous history of brucellosis and antimicrobial therapy and discontinuation of the therapy for any reason (allergy to any of the drugs, death, adverse reactions)

Date of first enrolment

01/01/2002

Date of final enrolment

31/12/2004

Locations

Countries of recruitment

Türkiye

Study participating centre Department of Infectious Disease

Kayseri Türkiye 38039

Sponsor information

Organisation

Erciyes University Medical School (Turkey)

Sponsor details

Department of Infectious Disease Erciyes University Medical School Kayseri Türkiye 38039 ealp@erciyes.edu.tr

Sponsor type

University/education

ROR

https://ror.org/047g8vk19

Funder(s)

Funder type

University/education

Funder Name

The study was supported by Infectious Disease Clinic, Erciyes University Medical School (Turkey)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	11/04/2006		Yes	No